Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line

Disulfiram and hydralazine have recently been reported to have anti-cancer action, and repositioned to be used as adjuvant in cancer therapy. Chemotherapy combined with other medications, such as those that affect the immune system or epigenetic cell profile, can overcome resistance with fewer adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Lafi, Zainab, Alshaer, Walhan, Gharaibeh, Lobna, Alqudah, Dana A., AlQuaissi, Baidaa, Bashaireh, Banan, Ibrahim, Abed Alqader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538757/
https://www.ncbi.nlm.nih.gov/pubmed/37768997
http://dx.doi.org/10.1371/journal.pone.0291981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538757/
https://www.ncbi.nlm.nih.gov/pubmed/37768997
http://dx.doi.org/10.1371/journal.pone.0291981

Ejemplares similares